Democritus University of Thrace, Department of Pulmonology, Alexandroupolis, Greece.
Expert Opin Pharmacother. 2012 May;13(7):1015-29. doi: 10.1517/14656566.2012.674513. Epub 2012 Apr 4.
Bronchodilators represent the mainstay of symptomatic treatment for chronic obstructive pulmonary disease (COPD). The principal bronchodilator agents are β(2)-agonists, anticholinergics and methylxanthines, used singly or in combination. Indacaterol is a novel long-acting β(2)-agonist for maintenance bronchodilator treatment of airflow obstruction in patients with COPD, approved in December 2009 by the European Medicines Association, and recently by the US Food and Drug Administration. It is administered once daily and is delivered by means of a single-dose dry powder inhaler (SDDPI). In Europe, the recommended dose is 150 μg and the maximum dose is 300 μg, while in the US the recommended dose is 75 μg. Indacaterol shows evidence of a rapid onset of bronchodilation, and its bronchodilatory duration is sustained.
Numerous clinical studies have assessed the therapeutic effects of indacaterol in various physiologic parameters, as well as symptoms, disease progression, exacerbation rates, quality of life, safety and tolerability. This review summarises published evidence regarding the efficacy, tolerability and safety of indacaterol in regard to lung function and symptoms of COPD patients.
Indacaterol, the novel once-daily β(2)-agonist, has rapid and sustained bronchodilatory effect, showing excellent efficacy, tolerability and safety, as shown by all clinical trials so far.
支气管扩张剂是治疗慢性阻塞性肺疾病（COPD）症状的主要方法。主要的支气管扩张剂有β(2)-激动剂、抗胆碱能药物和黄嘌呤衍生物，单独或联合使用。茚达特罗是一种新型长效β(2)-激动剂，用于 COPD 患者气流阻塞的维持治疗，于 2009 年 12 月被欧洲药品管理局批准，最近又被美国食品和药物管理局批准。它每天给药一次，通过单剂量干粉吸入器（SDDPI）给药。在欧洲，推荐剂量为 150μg，最大剂量为 300μg，而在美国的推荐剂量为 75μg。茚达特罗显示出快速起效的支气管扩张作用，其支气管扩张作用持续时间长。
许多临床研究评估了茚达特罗在各种生理参数、症状、疾病进展、恶化率、生活质量、安全性和耐受性方面的治疗效果。这篇综述总结了已发表的关于茚达特罗在肺功能和 COPD 患者症状方面的疗效、耐受性和安全性的证据。
新型每日一次的β(2)-激动剂茚达特罗具有快速而持久的支气管扩张作用，迄今为止的所有临床试验均显示出优异的疗效、耐受性和安全性。
